Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Account Payables: 2019-2024

Historic Change in Account Payables for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $871,000.

  • 4D Molecular Therapeutics' Change in Account Payables fell 261.61% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 334.60%. This contributed to the annual value of $871,000 for FY2024, which is 2.79% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Change in Account Payables stood at $871,000 for FY2024, which was down 2.79% from $896,000 recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Change in Account Payables peaked at $2.3 million during FY2021, and registered a low of -$1.6 million during FY2022.
  • Its 3-year average for Change in Account Payables is $43,000, with a median of $871,000 in 2024.
  • Its Change in Account Payables has fluctuated over the past 5 years, first skyrocketed by 5,213.95% in 2021, then tumbled by 171.68% in 2022.
  • Over the past 5 years, 4D Molecular Therapeutics' Change in Account Payables (Yearly) stood at $43,000 in 2020, then spiked by 5,213.95% to $2.3 million in 2021, then tumbled by 171.68% to -$1.6 million in 2022, then spiked by 154.70% to $896,000 in 2023, then fell by 2.79% to $871,000 in 2024.